Ever since doctors started replacing worn or damaged bones and teeth with plastic, metal, or ceramic parts, scientists have been on a quest to develop the perfect material for these orthopedic and dental implants. Initially, the challenge was to overcome the body's response to foreign materials, i.e. the strong tendency to reject them. While a lot of progress has been made, and millions of patients receive implants every year ranging from teeth to hip joints, medical implants still do not achieve the same fit and stability as the original tissue that they replace. Researchers have found that the response of host organisms to nanomaterials is different than that observed to conventional materials and that nanopatterning of the surface of implant materials therefore leads to much more compatible prostheses. One approach to improving the biological performance of implants is by functionalizing a non-physiological metallic implant surface through the application of biologically active coatings. Researchers in The Netherlands are now proposing a simple and cost-effective alternative to traditional biomedical coatings for bone implants.
In previous Spotlights we have addressed the numerous benefits that nanotechnology materials and applications could bring to the field of neural engineering and neural prostheses. Different biomedical devices implanted in the central nervous system, so-called neural interfaces, already have been developed to control motor disorders or to translate willful brain processes into specific actions by the control of external devices. Examples of existing brain implants include brain pacemakers, to ease the symptoms of such diseases as epilepsy, Parkinson's Disease, dystonia and recently depression; retinal implants that consist of an array of electrodes implanted on the back of the retina, a digital camera worn on the user's body, and a transmitter/image processor that converts the image to electrical signals sent to the brain. As promising as these new devices are, the reliability and robustness of neural interfaces is a major challenge due to the way brain tissue responds to the implant.
In the quest to make bone, joint and tooth implants almost as good as nature's own version, scientists are turning to nanotechnology. Researchers have found that the response of host organisms to nanomaterials is different than that observed to conventional materials. While this new field of nanomedical implants is in its very early stage, it holds the promise of novel and improved implant materials. One recent example is the nanopatterning of metal surfaces that promises to lead to superior medical implants. A multidisciplinary team of scientists have demonstrated that a simple and inexpensive chemical treatment can create nanopatterns on the surface of different implantable metals, such as Titanium, Tantalum, and CrCoMo alloys.
One of the many application areas that carbon nanotubes (CNTs) are experimented with is as a drug carrier in nanomedicine. Typically, nanoparticles have been used for drug delivery and it is only recently that carbon nanotubes have gained attention as potential drug delivery vehicles. Current research has shown the ability of CNTs to carry a variety of molecules such as drugs, DNA, proteins, peptides, targeting ligands etc. into cells - which makes them suitable candidates for targeted delivery applications. Polyethylene glycol (PEG) with molecular weight between 1 and 40 kDa is usually used to coat drug or imaging nanocarriers with the purpose of reducing non-specific interactions with cells and thus increasing the nanocarriers circulation time in vivo. However, when PEG in the form of PL-PEG (adsorbing phospholipid-PEG) has been used to functionalize single-walled CNTs, the finding were not consistent, sometimes even contradictory.
In a previous Nanotechnology Spotlight, we describe how, in order to develop tomorrow's supermaterials, scientists need to unlock nature's structural design rules, in particular for nanoscopic hierarchical molecular structures, and make them available to engineers. This is only possible through a deep understanding of the structure-property relations in biological materials. There is also a surprising relationship between these material design issues and the understanding (or rather lack thereof) of genetic diseases, where structural changes are due to mutations on the molecular level that lead to changed chemical and mechanical properties, which in turn lead to a malfunction of the protein network under mechanical load. Hierarchical nanostructures - ranging through atomistic, molecular and macroscopic scales - represent universal features of biological protein materials. New work by MIT professor Markus Buehler discusses the role of these structural hierarchies in determining properties of biological materials.
Collagen is one of the most essential and plentiful proteins in humans, making up about one quarter of all proteins in the body. It is also a major component of connective tissue such as cartilage, ligaments, tendons, bone and skin. Due to its excellent biocompatibility, biodegradability, and the ease of extraction, purification, and processing, collagen has found use as a versatile biomaterial in numerous medical applications. However, collagen is susceptible to biodegradation and the mechanical stability of native collagen for use in tissue repair is insufficient. In order to slow down the biodegradation rate, researchers have developed numerous chemical cross-linking techniques where individual protein chains are linked with a covalent bond, thereby stabilizing the protein. Scientists have now proposed a novel approach to collagen cross-linking on the basis of gold nanoparticles, opening a path to using collagen as a medium for delivery of drug molecules.
Typically, nanoparticles have been used for drug delivery and it has been only recently that carbon nanotubes (CNTs) have gained attention as potential drug delivery vehicles. Carbon nanotubes offer a number of advantages which suggest that they may provide an improved result over nanoparticles. They have a larger inner volume which allows more drug molecules to be encapsulated, and this volume is more easily accessible because the end caps can be easily removed, and they have distinct inner and outer surfaces for functionalization. Current research has shown the ability of CNTs to carry a variety of molecules such as drugs, DNA, proteins, peptides, targeting ligands etc. into cells - which makes them suitable candidates for targeted delivery applications. Despite these advantages, a suitable delivery system has not been developed yet for the targeted delivery of CNTs to specific sites.
A research team from various Canadian and U.S. universities has now demonstrated, for the first time, the design and development of a novel microcapsule carbon nanotube targeted delivery device.
Conventional vaccine development is based on the body's successful approach to dealing with viral infections. Unfortunately, standard vaccine technologies are ineffective against some of the most devastating infectious diseases such as HIV. A key role in developing cell-mediated immunity against viruses is played by so-called T-cells, which belong to a group of white blood cells known as lymphocytes. One variant of T-cells (cytotoxic T lymphocytes) directly attacks body cells that are infected with a virus or malignant or abnormal tumor cells. These 'killer' T-cells are called into action by 'helper' T-cells, which also activate other immune cells to produce antibodies. HIV, though, takes over helper T-cells and uses them to replicate itself. A major focus in AIDS research has therefore been the development of a 'T-cell vaccine' that induces T-cell immunity. While it was shown that peptides in blood could effectively stimulate T cell immunity in monkeys, and peptides are considered safe vaccine antigens, proteases in vivo can rapidly degrade peptide-based vaccines and this has limited their utility to date. New research by scientists in Australia represents an important finding for vaccine delivery as it demonstrates a feasible method for protecting biologically active peptides for delivery to antigen presenting cells (APCs).